GlaxoSmithKline, Valeant File Retigabine New Drug Application
LONDON -(Dow Jones)- GlaxoSmithKline PLC (GSK), a research-based
pharmaceutical and healthcare company, and Valeant Pharmaceuticals International
(VRX) said Monday that, on Oct. 30, they filed a new drug application with the
U.S. Food and Drug Administration and a marketing authorisation application with
the European Medicines Agency, for retigabine, used as adjunctive therapy to
treat adult epilepsy patients with partial-onset seizures.
MAIN FACTS:
-Retigabine is not approved or licensed anywhere in the world.
-By London Bureau, Dow Jones Newswires; Contact Ian Walker; +44 (0)20 7842 9296;
ian.walker@dowjones.com
(END) Dow Jones Newswires
11-02-090843ET
Copyright (c) 2009 Dow Jones & Company, Inc.
|